이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Seres Therapeutics 미래 성장

Future 기준 확인 1/6

Seres Therapeutics (는) 각각 연간 35.7% 및 17.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 44.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -417.8% 로 예상됩니다.

주요 정보

35.7%

수익 성장률

44.3%

EPS 성장률

Biotechs 수익 성장	24.5%
매출 성장률	17.8%
향후 자기자본 수익률	-417.8%
애널리스트 커버리지	Good
마지막 업데이트	06 Jun 2024

최근 미래 성장 업데이트

Recent updates

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

May 08

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Dec 27

Seres Therapeutics Molecular Data On SER-109 Looks Good

Oct 04

Seres Therapeutics: Here We Go Again

Sep 09

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Sep 03

Need To Know: Analysts Are Much More Bullish On Seres Therapeutics, Inc. (NASDAQ:MCRB) Revenues

Jul 03

Seres Therapeutics (MCRB) Presents At 2021 Jefferies Virtual Healthcare Conference - Slideshow

Jun 08

Seres Therapeutics gets FDA clearance for SER-155 IND trials

Jun 01

수익 및 매출 성장 예측

NasdaqGS:MCRB - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	85	-43	84	-141	5
12/31/2025	5	-146	-18	-147	7
12/31/2024	N/A	-160	-98	-102	7
3/31/2024	127	-83	-80	-76	N/A
12/31/2023	126	-114	-125	-117	N/A
9/30/2023	127	-141	-133	-123	N/A
6/30/2023	130	-153	-133	-123	N/A
3/31/2023	5	-265	-250	-239	N/A
12/31/2022	7	-250	-239	-229	N/A
9/30/2022	13	-231	-236	-228	N/A
6/30/2022	137	-103	-51	-40	N/A
3/31/2022	141	-87	-41	-30	N/A
12/31/2021	145	-66	-3	7	N/A
9/30/2021	155	-34	32	41	N/A
6/30/2021	30	-132	-117	-113	N/A
3/31/2021	31	-105	-101	-99	N/A
12/31/2020	33	-89	-94	-94	N/A
9/30/2020	23	-90	-90	-90	N/A
6/30/2020	29	-76	-83	-82	N/A
3/31/2020	35	-66	-69	-68	N/A
12/31/2019	35	-70	-78	-77	N/A
9/30/2019	38	-73	-50	-50	N/A
6/30/2019	40	-78	-56	-55	N/A
3/31/2019	32	-95	-70	-68	N/A
12/31/2018	28	-99	-65	-63	N/A
9/30/2018	21	-107	-99	-96	N/A
6/30/2018	35	-92	-79	-77	N/A
3/31/2018	33	-92	-80	-77	N/A
12/31/2017	32	-89	N/A	-76	N/A
9/30/2017	32	-86	N/A	-76	N/A
6/30/2017	22	-97	N/A	-83	N/A
3/31/2017	22	-97	N/A	-83	N/A
12/31/2016	22	-92	N/A	44	N/A
9/30/2016	19	-86	N/A	53	N/A
6/30/2016	6	-82	N/A	53	N/A
3/31/2016	3	-67	N/A	69	N/A
12/31/2015	N/A	-55	N/A	-41	N/A
9/30/2015	N/A	-44	N/A	-33	N/A
6/30/2015	N/A	-34	N/A	-25	N/A
3/31/2015	N/A	-24	N/A	-17	N/A
12/31/2014	N/A	-18	N/A	-10	N/A
9/30/2014	N/A	-12	N/A	-8	N/A

애널리스트 미래 성장 예측

수입 대 저축률: MCRB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: MCRB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: MCRB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: MCRB 의 수익(연간 17.8% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: MCRB 의 수익(연간 17.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: MCRB (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

Seres Therapeutics 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 14% to US$6.20

Consensus revenue estimates decrease by 63%, EPS upgraded

No longer forecast to breakeven

Price target increased by 7.7% to US$9.02

Price target increased by 15% to US$9.80

Forecast to breakeven in 2026

Recent updates

Nestle's Health Unit to Take Full Control of Microbiota-Based Therapeutic

New minor risk - Market cap size

Price target decreased by 14% to US$6.20

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

New minor risk - Market cap size

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Consensus revenue estimates decrease by 63%, EPS upgraded

New minor risk - Financial position

Full year 2023 earnings: EPS exceeds analyst expectations

No longer forecast to breakeven

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Price target increased by 7.7% to US$9.02

Price target increased by 15% to US$9.80

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Forecast to breakeven in 2026

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Consensus EPS estimates upgraded to US$0.98 loss, revenue downgraded

Price target decreased by 13% to US$8.54

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Seres Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Consensus EPS estimates fall by 34%

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Second quarter 2023 earnings: EPS misses analyst expectations

Second quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 7.6% to US$10.17

Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™

Consensus EPS estimates upgraded to US$0.96 loss

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.61 loss in 1Q 2022)

Consensus estimates of losses per share improve by 13%

Price target decreased by 11% to US$11.00

Full year 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics' Investigational Ser-109 Ecospor Iv Study Data Publishes in Jama Network Open

Seres Therapeutics, Inc. Announces Initiation of Enrollment in SER-155 Phase 1B Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Consensus forecasts updated

Price target increased to US$14.33

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics, Inc. Announces the Publication of Phase 3 Clinical Data in the Journal of the American Medical Association

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Consensus revenue estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Seres Therapeutics: The Good And The Challenging

Seres Therapeutics stock slips on $100M stock offering

Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

Seres Therapeutics, Inc. Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection At the Digestive Disease Week (Ddw) Annual Meeting

Consensus revenue estimates fall by 64%

Price target decreased to US$17.57

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Consensus revenue estimates fall by 30%

Seres Therapeutics Is Playing A Long Game

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind